What is OBIO's P/E ratio?

ORCHESTRA BIOMED HOLDINGS INC. (OBIO) currently trades at a P/E ratio of 38.55.

ORCHESTRA BIOMED HOLDINGS INC. reports a Return on Equity (ROE) of -107.20%.

What is OBIO's dividend yield?

ORCHESTRA BIOMED HOLDINGS INC. offers a dividend yield of 0.00%.

What is OBIO's Deepscope Quality Score?

Deepscope rates OBIO's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy OBIO?

Deepscope's AI Timing Score for OBIO is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does OBIO belong to?

ORCHESTRA BIOMED HOLDINGS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

หุ้น OBIO (NASDAQ) | ORCHESTRA BIOMED HOLDINGS INC. – วิเคราะห์โดย Deepscope

Stock Check ข้อมูลอัปเดตรายวัน ที่เวลา 09.30 น.
(Price: 2026-06-11 | FS: 2026-03-31)

OBIO

ORCHESTRA BIOMED HOLDINGS INC.

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 4.07

0.05 (1.24%) Day Change

Watchlist Portfolio Compare Chart

38.55

P/E

0.30

D/E

-107.2%

ROE

-54.3%

ROA

0.00%

Div Yield

16.54

PEG

ORCHESTRA BIOMED HOLDINGS INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 4.07 Price 0.05 (1.24%) Day Change	NEWS SCORE: 99

OBIO มีคุณภาพโดยรวมไม่ดี ( คะแนนปัจจัยพื้นฐาน = 38) และ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: อัตราผลตอบแทนผู้ถือหุ้น (ROE) ค่อนข้างต่ำ
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ในอดีต ค่อนข้างต่ำ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ลดลงอย่างมีนัยยะสำคัญ
อัตราการเติบโตของอัตราผลตอบแทนสินทรัพย์(ROA) ปัจจุบันต่ำกว่าเกณฑ์
อัตรากำไรสุทธิ ค่อนข้างต่ำ
อัตราเร่งของการเติบโตของอัตรากำไรสุทธิ ต่ำกว่าเกณฑ์
อัตรากำไรสุทธิในอดีต ค่อนข้างต่ำ

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ไม่ดี สุขภาพทางการเงิน ไม่ดี และ ประสิทธิภาพการทำกำไร พอใช้ , ...

ปัจจัยทางคุณภาพ

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	4.07
PBV / Sector	4.72 / 4.79
Earning Per Share	-0.92

PE / Sector	38.55 / 18.05
PEG or PE/Growth / Sector	16.54 / 0.62
Average 1M Daily Value	1.01 M GREAT
Average 1W Daily Value	0.70 M GREAT

ปัจจัยทางเทคนิค

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

สุขภาพทางการเงิน

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ประสิทธิภาพการทำกำไร

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-166.96 / 468.85
NPM Average (%) / Sector	-1,073.72 / -1,531.69
NPM Change Average (%) / Sector	7.49 / 5,028.65
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-54.28 / 31.69
ROA Average (%) / Sector	-53.41 / -353.18
ROA Change Average (%) / Sector	19.39 / 5,214.65 GOOD
ROE (%) / Sector	-107.20 / 10.58
ROE Average (%) / Sector	-102.34 / 27.64
ROE Change Average (%) / Sector	35.79 / 2,048.88 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

ผลตอบแทนต่อผู้ถือหุ้น

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.77

รายละเอียดการจดทะเบียน

Analyze Date	2026-06-12 09:42:55
Symbol	OBIO
Name	ORCHESTRA BIOMED HOLDINGS INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	59.88 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	240.72 / 9,010.81

ข่าว, ประมาณการ, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 150 Union Square Drive, New Hope, PA, United States, 18938

Phone: 215 862 5797

Website: https://www.orchestrabiomed.com

Employees: 86

Sector: Healthcare >> Biotechnology

Description: Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.